Table 3 Individual clinical data of study participants with rFSGS (N = 5).
Patient number | Day of recurrence post-transplant | Primary PP response | PP dependence | Rituximab treatment | Rituximab side effects | Other treatments tried | Remission at current time | PP dependence post rituximab | Follow up duration (months) | Graft function (eGFR ml/min/1/.73BSA) |
|---|---|---|---|---|---|---|---|---|---|---|
3 | 3 | Remission | No | No | - | High dose cyclosporine | Complete (at graft loss) | - | 61 | Graft loss due to humoral rejection (5) |
4 | 7 | Remission with further relapse | Yes | Yes | No | LDL apheresis | Complete | Yes Weekly | 76 | Functioning graft (100) |
5 | 2 | Remission | Yes | Yes (3rd recurrence) | No | Complete | No | 64 | Functioning graft (102) | |
6 | 1 | Partial | Yes | Yes | Serum sickness | LDL apheresis | Complete | No | 19 | Functioning graft (97) |
7 | 2 | Partial | Yes | Yes | No | High doe cyclosporine | Complete | No | 20 | Functioning graft (77) |
8 | 60 | Partial | Yes | Yes | Mild allergic reaction | Partial U Pr/cr 0.4 | Yes Weekly | 12 | Functioning graft (108) | |
Total | Average 12.5d (+/-23) Median 2.5d | 50% complete remission | Yes 83% | Yes 83% | 1 severe side effect 1 mild side effect | 100% remission (Complete/ Partial) | No 67% | Average 42 m Median 40.5 m | 1 graft loss |
